United States Department of Veterans Affairs
Research Advisory Committee on Gulf War Veterans' Illnesses

Research Update - March 2006

 

The following journal articles were distributed for review in March 2006.  The hyperlinks are directed to the article's abstract on PubMed.

Research Relevant to Gulf War Service and Exposures
 
1. Health of Gulf War Veterans.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361.
 
2. Introduction. The Health of Gulf War Veterans.   (Wessely S.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 531-532)
 
3. Historical approaches to post-combat disorders.   (Jones E.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 533-542)
 
4. Multi-symptom illnesses, unexplained illness and Gulf War Syndrome.   (Ismail K.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 543-551)
 
5. Healthcare utilization and mortality among veterans of the Gulf War.   (Gray GC, Kang HN.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 553-569)
 
6. Reproductive health of Gulf War veterans.   (Doyle P, et al.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 571-584)
 
7. Stress and stressors of the early phases of the Persian Gulf War.   (Gifford RK, et al.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 585-591)
 
8. The impact of the 1991 Gulf War on the mind and brain: findings from neuropsychological and neuroimaging research.   (Vasterling JJ, Bremner JD.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 593-604)
 
9. Neurological disorders in Gulf War veterans.   (Rose MR, Brix KA.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 605-618)
 
10. Gulf War illness: a view from Australia.   (Sim M, Kelsall H. Philos Trans R Soc Lond B Biol Sci .   Mar 24, 2006; 361: 619-626)
 
11. The challenges of exposure assessment in health studies of Gulf War veterans.   (Glass DC , Sim MR.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 627-637)
 
12. Depleted uranium exposure and health effects in Gulf War veterans.   (Squibb KS , McDiarmid MA.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 639-648)
 
13. Toxicological assessments of Gulf War veterans.   (Brown M.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 649-679)
 
14. Immunological dysfunction, vaccination and Gulf War illness.   (Peakman M, et al.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 681-687)
 
15. Risk and the social construction of ‘Gulf War Syndrome’.   (Durodie B.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 689-695)
 
16. On being a Gulf veteran: an anthropological perspective.   (Kilshaw S.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 697-706)
 
17. Managing future Gulf War Syndromes: international lessons and new models of care.   (Engel CC, et al.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 707-720)
 
18. Reflections on Gulf War illness. (Wessely S, Freedman L.  Philos Trans R Soc Lond B Biol Sci.   Mar 24, 2006; 361: 721-730)
 
19. Seizure duration following sarin exposure affects neuro-inflammatory markers in the rat brain.   (Chapman S, et al.  Neurotoxicology.  Mar 2006; 27(2): 277-283)
 
20. Synergism between insecticides permethrin and propoxur occurs through activation of presynaptic muscarinic negative feedback of acetylcholine release in the insect central nervous system.   (Corbel V, et al.  Neurotoxicology.  Mar 2, 2006; [Epub ahead of print])
 
21. Treatment of the stress casualty during Operation Iraqi Freedom One.   (Forsten R, Schneider B.  Psychiatr Q.  Winter 2005; 76(4): 343-350)
 
22. Clinical diagnostic indicators of renal and bone damage in rats intramuscularly injected with depleted uranium.   (Fukuda S, et al.  Radiat Prot Dosimetry.  Jan 25, 2006; [Epub ahead of print])
 
23. Fatal motor vehicle crashes among veterans of the 1991 Gulf War and exposure to munitions demolitions at Khamisiyah: A nested case-control study.  (Gackstetter GD, et al.  Am J Ind Med.  Mar 2006; 49(4): 261-270)
 
24. Nephrotoxicty of uranyl acetate: Effect on rat kidney brush border membrane vesicles.  (Goldman M, et al.  Arch Toxicol.  Feb 16, 2006; [Epub ahead of print])
 
25. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan.   (Hoge CW, et al.  JAMA.  Mar 1, 2006; 295(9): 1023-1032)
 
26. Chronic widespread pain and psychiatric disorders in veterans of the first Gulf War.   (Kuzma JM, Black DW.  Curr Pain Headache Rep.  Apr 2006; 10(2): 85-89)
 
27. Gulf War illnesses.   (Lee HA.  Br J Hosp Med (Lond).  Dec 2005; 66(12): 706)
 
28. Motor vehicle fatalities among Gulf War era veterans: Characteristics, mechanisms, and circumstances.   (Lincoln AE, et al.  Traffic Inj Prev.  Mar 2006; 7(1): 31-37)
 
29. Lateral parabrachial lesions disrupt paraoxon-induced conditioned flavor avoidance.   (Lopez-Grancha M, et al.  Toxicol Sci.  Feb 13, 2006 [Epub ahead of print])
 
30. Hazardous or harmful alcohol use in Royal Australian Navy veterans of the 1991 Gulf War: Identification of high risk subgroups.   (McKenzie DP, et al.  Addict Behav.  Feb 3, 2006; [Epub ahead of print])
 
31. Virtues and woes of AChE alternative splicing in stress-related neuropathologies.   (Meshorer E, Soreq H.  Trends Neurosci.  Mar 2, 2006; [Epub ahead of print])
 
32. Anticholinesterase toxicity and oxidative stress.   (Milatovic D, et al.  ScientificWorldJournal.  Feb 28, 2006; 295-310)
 
33. UK armed forces responses to an informed consent policy for anthrax vaccination: A paradoxical effect?   (Murphy D, et al.  Vaccine.  Feb 3,2006; [Epub ahead of print])
 
34. Health effects in Army Gulf War veterans possibly exposed to chemical munitions destruction at Khamisiyah , Iraq : Part I. Morbidity associated with potential exposure.   (Page WF, et al.  Mil Med.  Nov 2005; 170(11): 935-944)
 
35. Health effects in Army Gulf War veterans possibly exposed to chemical munitions destruction at Khamisiyah , Iraq : Part II. Morbidity associated with notification of potential exposure. (Page WF, et al.  Mil Med.  Nov 2005; 170(11): 945-951)
 
36. Identification of potential CFS biomarkers in ALS.   (Pasinetti GM, et al.  Neurology.  Feb 15, 2006; [Epub ahead of print])
 
37. Development of the Vaccine Analytic Unit’s research agenda for investigating potential adverse events associated with anthrax vaccine absorbed.   (Payne DC , et al.  Pharmacoepidemiol Drug Saf.  Jan 30, 2006; [Epub ahead of print])
 
38. Stress adversely affects efficacy of physostigmine-scopolamine pretreatment against soman in guinea pigs.   (Philippens IH, et al.  Pharmacol Biochem Behav.  Sep 2005; 82(1): 125-132. [Epub Aug 26, 2005])
 
39. Combat effects on mental health: the more things change, the more they remain the same.   (Pitman RK.  Arch Gen Psychiatry.  Feb 2006; 63(2): 127-128)
 
40. Physical and mental health costs of traumatic war experiences among Civil War veterans.   (Pizarro J, et al.  Arch Gen Psychiatry.  Feb 2006; 63(2): 193-200)
 
41. Examination of concurrent exposure to repeated stress and chlorpyrifos on cholinergic, glutamaterigc, and monoamine neurotransmitter systems in rat forebrqain regions.   (Pung T, et al.  Int J Toxicol.  Jan-Feb 2006; 25(1): 65-80)
 
42. Self-reported description of diarrhea among military populations in Operations Iraqi Freedom and Enduring Freedom.   (Putnam SD , et al.  J Travel Med.  Mar-Apr2006; 13(2): 92-99)
 
43. Health consequences of the first Persian Gulf War on French troops.   (Salamon R, et al.  Int J. Epidemiol.  Jan 24, 2006; [Epub ahead of print])
 
44. Rapid and reliable diagnostic tests for visceral leishmaniasis.   (Salotra P, Singh R.  Indian J Med Res.  Dec 2005; 122: 464-467)
 
45. Long-term effects of sarin.   (Sharp D. Lancet. Jan 14, 2006; 367(9505): 95-97)
 
46. The effects of repeated low-dose sarin exposure.   (Shih TM, et al.  Toxicol Appl Pharmacol.  Mar 21, 2006; [Epub ahead of print])
 
47. Systematic review of multi-symptom conditions in Gulf War veterans.   (Thomas HV, et al.  Psychol Med.  Jan 26, 2006; 1-13 [Epub ahead of print])
 
48. Effects of depleted uranium after short-term exposure on vitamin D metabolism in rat.   (Tissandie E, et al.  Arch Toxicol.  Feb 25, 2006; [Epub ahead of print])
 
49. Mental distress among younger veterans before, during, and after the invasion of Iraq.   (West AN, Weeks WB.  Psychiatr Serv. Feb 2006; 57(2): 244-248)
 
50. Toxicity of jet fuel aliphatic and aromatic hydrocarbon mixtures on human epidermal kerantinocytes: Evaluation based on in vitro cytotoxicity and interleukin-8 release.  (Yang JH, et al.  Arch Toxicol.  Feb 17, 2006; [Epub ahead of print])
 
Research on Evaluation/Treatment of Chronic Multisymptom Illnesses
 
1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome ?  (Blockmans D, et al.  Am J Med.  Feb 2006; 119(2): 167.e23-30)
 
2. The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome.   (Geisser ME, et al.  Eur J Pain.  Mar 16, 2006; [Epub ahead of print])
 
3. Treatment of Chronic Fatigue Syndrome with antibiotics: pilot study assessing the involvement of Coxiella burnetti infection.   (Iwakami E, et al.  Intern Med.  Dec 2005; 44(12): 1258-1263)
 
4. Sub-typing CFS patients on the basis of ‘minor’ symptoms.   (Janal MN, et al.  Biol Psychol.  Feb 9, 2006; [Epub ahead of print])
 
5. Diurnal excretion of urinary cortisol, cortisone, and cortisol metabolites in Chronic Fatigue Syndrome. (Jerjes WK, et al.  J Psychosom Res.  Feb 2006; 60(2): 145-153)
 
6. Is Chronic Fatigue Syndrome associated with platelet activation?  (Kennedy G, et al.  Blood Coagul Fibrinolysis.  Mar 2006; 17(2): 89-92)
 
7. Do Topical Herbal Agents Provide Pain Relief?  (Ko GD, et al.  Pract Pain Manage J.  Jan-Feb 2006; 62-71)
 
8. Fibromyalgia syndrome: which antidepressant drug should we choose?   (Littlejohn GO, Guymer EK.  Curr Pharm Des.  2006; 12(1): 3-9)
 
9. Chemosensory function and psychological profile in patients with multiple chemical sensitivity: Comparison with odor-sensitive and asymptomatic controls.   (Papo D, et al.  J Psychom Res. Feb 2006; 60(2): 199-209)
 
10. Complementary and alternative medical therapies in fibromyalgia.   (Sarac AJ, Gur A.  Curr Pharm Des.  2006; 12(1): 47-57)
 
11. Effectiveness of acupuncture in the treatment of fibromyalgia.   (Singh BB, et al.  Altern Ther Health Med.  Mar-Apr 2006; 12(2): 34-41)
 
12. Are tender point injections beneficial: the role of tonic nociception in fibromyalgia?   (Staud R.  Curr Pharm Des.  2006; 12(1): 23-27)
 
13. Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion.  (van Heukelom RO, et al.  Eur J Neurol.  Jan 2006; 13(1): 55-60)
 
14. Challenges for molecular profiling of chronic fatigue syndrome.   (Vernon SD , et al.  Pharmacogenomics.  Mar 2006; 7(2): 211-218)
 
15. Is there a role for cytokine based therapies in fibromyalgia?  (Wallace DJ.  Curr Pharm Des.  2006: 12(1): 17-22)
 
16. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow.   (Yoshiuchi K, et al.  Clin Physiol Funct Imaging.  Mar 2006; 26(2): 83-86)